Advertisement

Coccidioidomycosis: Epidemiology, Fungal Pathogenesis, and Therapeutic Development

  • Hazael Hernandez
  • Victor H. Erives
  • Luis R. MartinezEmail author
Tropical Mycosis (L Martinez, Section Editor)
  • 7 Downloads
Part of the following topical collections:
  1. Topical Collection on Tropical Mycosis

Abstract

Purpose of Review

Coccidioidomycosis can result from the inhalation of infectious spores of Coccidioides species (spp.) immitis or posadasii. Clinical manifestations range from mild flu-like disease to severe disseminated infection that can require life-long therapy. Burden of this mycosis is high in the southwest region of the USA where it is well characterized, and in many areas of Mexico and Latin America where it is inadequately characterized. Here, we provide historical data and current knowledge on Coccidioides spp. pathogenesis as well as recent progress in therapeutic and vaccine development against coccidioidomycosis.

Recent Findings

The virulence mechanisms of Coccidioides spp. are largely unknown; however, production and regulation of a spherule glycoprotein, ammonium production, and melanization have all been proposed as integral factors in Coccidioides spp.’ pathogenesis. Therapeutic options are limited and not 100% effective, but individualized treatment with triazoles or amphotericin B over the course of pulmonary or disseminated infection can be effective in resolution of coccidioidomycosis. Human immunization has not been achieved but efforts are ongoing.

Summary

Advances in therapeutic and vaccine development are imperative for the prevention and treatment of coccidioidomycosis, especially for those individuals at risk either living or traveling to or from endemic areas.

Keywords

Antifungals Coccidioidomycosis Epidemiology Vaccine Valley fever Virulence 

Notes

Acknowledgements

The authors would like to thank Joshua D. Nosanchuk, M.D., for providing his review of the manuscript.

Funding Information

H. H. was supported by National Institute of General Medical Sciences (NIGMS) RISE training grant R25 GM069621-15. L.R.M. was partially supported by the National Institute of General Medical Sciences of the U.S. National Institutes of Health (NIH) under award number 1R15GM117501-01A1. L.R.M. is partially funded and has an appointment in the Infectious Diseases and Immunology cluster of the Border Biomedical Research Center (BBRC; National Institute on Minority Health and Health Disparities award number 2G12MD007592), UTEP’s Research Centers in Minority Institutions Program.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance ••Of major importance

  1. 1.
    Huppert M, Sun SH, Harrison JL. Morphogenesis throughout saprobic and parasitic cycles of Coccidioides immitis. Mycopathologia. 1982;78(2):107–22.CrossRefPubMedGoogle Scholar
  2. 2.
    Fisher MC, Koenig GL, White TJ, Taylor JW. Molecular and phenotypic description of Coccidioides posadasii sp. nov., previously recognized as the non-California population of Coccidioides immitis. Mycologia. 2002;94(1):73–84.CrossRefPubMedGoogle Scholar
  3. 3.
    Rixford E, Gilchrist TC. Two cases of protozoan (coccidioidal) infection of the skin and other organs. Johns Hopkins Hosp Rep. 1896;10:209–68.Google Scholar
  4. 4.
    Ophuls W. Further observations on a pathogenic mould formerly described as a protozoon (Coccidioides immitis, Coccidioides pyogenes). J Exp Med. 1905;6(4–6):443–85.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Posadas A. Un nuevo caso de micosis fungoidea con posrospemias. An Cir Med Argent. 1892;15:585–97.Google Scholar
  6. 6.
    Ampel NM, Hector RF. Measuring cellular immunity in coccidioidomycosis: the time is now. Mycopathologia. 2010;169(6):425–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Whiston E, Zhang Wise H, Sharpton TJ, Jui G, Cole GT, Taylor JW. Comparative transcriptomics of the saprobic and parasitic growth phases in Coccidioides spp. PLoS One. 2012;7(7):e41034.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Johnson RH, Stevens DA, et al. Coccidioidomycosis. Clin Infect Dis. 2005;41(9):1217–23.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Sondermeyer G, Lee L, Gilliss D, Tabnak F, Vugia D. Coccidioidomycosis-associated hospitalizations, California, USA, 2000-2011. Emerg Infect Dis. 2013;19(10):1590–7.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    • Hirschmann JV. The early history of coccidioidomycosis: 1892-1945. Clin Infect Dis. 2007;44(9):1202–7 This review describes the discovery and early characterization of Coccidioides spp. up until 1945 and highlights some of the key early Coccidioides sp. investigators like CE Smith and their contributions. CrossRefPubMedGoogle Scholar
  11. 11.
    Davis BL, Smith RT, Smith CE. An epidemic of coccidioidal infection (coccidioidomycosis). JAMA. 1942;118:1182–6.CrossRefGoogle Scholar
  12. 12.
    Dickson EC. Coccidioides infection (coccidioidomycosis): II. The primary type of infection. Arch Intern Med. 1938;62(5):853–71.CrossRefGoogle Scholar
  13. 13.
    • Nguyen C, Barker BM, Hoover S, Nix DE, Ampel NM, Frelinger JA, et al. Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis. Clin Microbiol Rev. 2013;26(3):505–25 This review summarizes many aspects of Coccidioides spp. such as their mycology, population genetics, epedemiology, clinical managements, and diagnostic testing. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Butkiewicz CD, Shubitz LF. Coccidioidomycosis in alpacas in the southwestern United States. Transbound Emerg Dis. 2019;66(2):807–12.CrossRefPubMedGoogle Scholar
  15. 15.
    Graupmann-Kuzma A, et al. Coccidioidomycosis in dogs and cats: a review. J Am Anim Hosp Assoc. 2008;44(5):226–35.CrossRefPubMedGoogle Scholar
  16. 16.
    Blundell GP, et al. The pathology of Coccidioides immitis in the Macaca mulatta. Am J Pathol. 1961;39:613–30.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Converse JL, et al. Pathogenesis of Coccidioides immitis in monkeys. J Bacteriol. 1962;83:871–8.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Converse JL. Effect of physico-chemical environment of spherulation of Coccidioides immitis in a chemically defined medium. J Bacteriol. 1956;72(6):784–92.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Galgiani JN, Hayden R, Payne CM. Leukocyte effects on the dimorphism of Coccidioides immitis. J Infect Dis. 1982;146(1):56–63.CrossRefPubMedGoogle Scholar
  20. 20.
    Hector RF, Rutherford GW, Tsang CA, Erhart LM, McCotter O, Anderson SM, et al. The public health impact of coccidioidomycosis in Arizona and California. Int J Environ Res Public Health. 2011;8(4):1150–73.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Sharma S, Thompson GR III. How I treat coccidioidomycosis. Curr Fungal Infect Rep. 2012;7:29–35.CrossRefGoogle Scholar
  22. 22.
    Buhrow SM. Coccidioidomycosis: a differential diagnosis for visitors to the southwest. Am J Nurs. 2013;113(11):52–5.CrossRefPubMedGoogle Scholar
  23. 23.
    •• Laniado-Laborin R, et al. Coccidioidomycosis in Latin America. Med Mycol. 2019;57(Supplement_1):S46–55 This study reviews cases of coccidioidomycosis in Mexico, Central America, and South America and highlights molecular studies of Coccidioides spp. performed from with human, enviromental, and animal samples from Mexico. CrossRefPubMedGoogle Scholar
  24. 24.
    Cox RA, Magee DM. Coccidioidomycosis: host response and vaccine development. Clin Microbiol Rev. 2004;17(4):804–39 table of contents.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Johnson R, Ho J, Fowler P, Heidari A. Coccidioidal meningitis: a review on diagnosis, treatment, and management of complications. Curr Neurol Neurosci Rep. 2018;18(4):19.CrossRefPubMedGoogle Scholar
  26. 26.
    Ampel NM. The treatment of coccidioidomycosis. Rev Inst Med Trop Sao Paulo. 2015;57(Suppl 19):51–6.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Garcia Garcia SC, Salas Alanis JC, Flores MG, Gonzalez Gonzalez SE, Vera Cabrera L, Ocampo Candiani J. Coccidioidomycosis and the skin: a comprehensive review. An Bras Dermatol. 2015;90(5):610–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Chang A, et al. Primary cutaneous coccidioidomycosis. J Am Acad Dermatol. 2003;49(5):944–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Shiu J, Thai M, Elsensohn AN, Nguyen NQ, Lin KY, Cassarino DS. A case series of primary cutaneous coccidioidomycosis after a record-breaking rainy season. JAAD Case Rep. 2018;4(5):412–4.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    • Brown J, et al. Coccidioidomycosis: epidemiology. Clin Epidemiol. 2013;5:185–97 This review examines the history, ecology, and epidemiology of Coccidioides spp. and highlights risk factors such as age, gender, race, pregnancy, transplant, immunosuppression, and imprisonment in Southwest prisons. PubMedPubMedCentralGoogle Scholar
  31. 31.
    Colombo AL, Tobón A, Restrepo A, Queiroz-Telles F, Nucci M. Epidemiology of endemic systemic fungal infections in Latin America. Med Mycol. 2011;49(8):785–98.PubMedGoogle Scholar
  32. 32.
    Fisher MC, Koenig GL, White TJ, San-Blas G, Negroni R, Alvarez IG, et al. Biogeographic range expansion into South America by Coccidioides immitis mirrors New World patterns of human migration. Proc Natl Acad Sci U S A. 2001;98(8):4558–62.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    •• Wilson L, et al. The rise of valley fever: prevalence and cost burden of coccidioidomycosis infection in California. Int J Environ Res Public Health. 2019;16(7) This study assesses the economics of the morbidity and mortality associated with coccidioidomycosis in California such as the costs resulting from uncomplicated pneumonia, chronic pneumonia, and disseminated disease. Google Scholar
  34. 34.
    Centers for Disease, C., Valley fever awareness (https://www.cdc.gov/features/valleyfever/index.html). 2019.Google Scholar
  35. 35.
    UC Davis information on valley fever (https://health.ucdavis.edu/medmicro/cocci.html). 2019.
  36. 36.
    Centers for Disease, C., Valley fever (coccidioidomycosis) statistics (https://www.cdc.gov/fungal/diseases/coccidioidomycosis/statistics.html). 2019.
  37. 37.
    NIH, U.S., Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis (valley fever) and other select endemic fungal infections (https://grants.nih.gov/grants/guide/pa-files/PA-19-082.html). 2018.
  38. 38.
    Benedict K, Park BJ. Invasive fungal infections after natural disasters. Emerg Infect Dis. 2014;20(3):349–55.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Hernandez H, Martinez LR. Relationship of environmental disturbances and the infectious potential of fungi. Microbiology. 2018;164(3):233–41.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Schneider E, Hajjeh RA, Spiegel RA, Jibson RW, Harp EL, Marshall GA, et al. A coccidioidomycosis outbreak following the Northridge, Calif, earthquake. JAMA. 1997;277(11):904–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Flynn NM, et al. An unusual outbreak of windborne coccidioidomycosis. N Engl J Med. 1979;301(7):358–61.CrossRefPubMedGoogle Scholar
  42. 42.
    Williams PL, Sable DL, Mendez P, Smyth LT. Symptomatic coccidioidomycosis following a severe natural dust storm. An outbreak at the Naval Air Station, Lemoore, Calif. Chest. 1979;76(5):566–70.CrossRefPubMedGoogle Scholar
  43. 43.
    Pappagianis D, Einstein H. Tempest from Tehachapi takes toll or Coccidioides conveyed aloft and afar. West J Med. 1978;129(6):527–30.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Tong DQ, Wang JXL, Gill TE, Lei H, Wang B. Intensified dust storm activity and valley fever infection in the southwestern United States. Geophys Res Lett. 2017;44(9):4304–12.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Tamerius JD, Comrie AC. Coccidioidomycosis incidence in Arizona predicted by seasonal precipitation. PLoS One. 2011;6(6):e21009.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Talamantes J, Behseta S, Zender CS. Fluctuations in climate and incidence of coccidioidomycosis in Kern County, California: a review. Ann N Y Acad Sci. 2007;1111:73–82.CrossRefPubMedGoogle Scholar
  47. 47.
    Cummings KC, et al. Point-source outbreak of coccidioidomycosis in construction workers. Epidemiol Infect. 2010;138(4):507–11.CrossRefPubMedGoogle Scholar
  48. 48.
    Coates SJ, Fox LP. Disseminated coccidioidomycosis as a harbinger of climate change. JAAD Case Rep. 2018;4(5):424–5.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Weaver EA, Kolivras KN. Investigating the relationship between climate and valley fever (coccidioidomycosis). Ecohealth. 2018;15(4):840–52.CrossRefPubMedGoogle Scholar
  50. 50.
    Hawryluk M., Traces of valley fever fungus found in Central Oregon (http://www.bendbulletin.com/home/4524652-151/traces-of-valley-fever-fungus-found-in-central%0D%0A). The Bulletin, 2016.
  51. 51.
    Marsden-Haug N, et al. Coccidioidomycosis acquired in Washington State. Clin Infect Dis. 2013;56(6):847–50.CrossRefPubMedGoogle Scholar
  52. 52.
    Johnson SM, Carlson EL, Fisher FS, Pappagianis D. Demonstration of Coccidioides immitis and Coccidioides posadasii DNA in soil samples collected from Dinosaur National Monument, Utah. Med Mycol. 2014;52(6):610–7.CrossRefPubMedGoogle Scholar
  53. 53.
    Bialek R, Kern J, Herrmann T, Tijerina R, Cecenas L, Reischl U, et al. PCR assays for identification of Coccidioides posadasii based on the nucleotide sequence of the antigen 2/proline-rich antigen. J Clin Microbiol. 2004;42(2):778–83.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Madrid GS. Coccidioidomicosis, vol. 6: Prensa Medica; 1946. p. 1033–5.Google Scholar
  55. 55.
    Madrid GS. Las micosis pulmonares. Rev Mex Tuber Ap Resp. 1948;9:32–55.Google Scholar
  56. 56.
    Sotomayor C, Madrid GS, Torres EA. Aislamiento de Coccidioides immitis del suelo de Hermosillo, Sonora México. Rev Latinoam Microbiol. 1960;3:237–8.Google Scholar
  57. 57.
    Baptista Rosas RC, Riquelme M. The epidemiology of coccidioidomycosis in Mexico. Rev Iberoam Micol. 2007;24(2):100–5.CrossRefPubMedGoogle Scholar
  58. 58.
    Gonzalez-Benavides J. The panorama of coccidioidomycosis in Nuevo Leon from 1978 to 1988. Gac Med Mex. 1991;127(5):427–32 discussion 432–3.PubMedGoogle Scholar
  59. 59.
    Laniado Laborin R, Moreno RPC, Cerro MA. Tijuana: endemic zone of Coccidioides immitis infection. Salud Publica Mex. 1991;33(3):235–9.PubMedGoogle Scholar
  60. 60.
    Ajello L. Comparative ecology of respiratory mycotic disease agents. Bacteriol Rev. 1967;31(1):6–24.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Mondragon-Gonzalez R, et al. Detection of Coccidioides immitis infection in Coahuila, Mexico. Rev Argent Microbiol. 2005;37(3):135–8.PubMedGoogle Scholar
  62. 62.
    Tucker HA. Histoplasmin, tuberculin and coccidioidin sensitivity on the Isthmus of Panama; preliminary report of 500 patients. Am J Trop Med Hyg. 1950;30(6):865–70.CrossRefPubMedGoogle Scholar
  63. 63.
    Andrade M. Investigation of coccidioidomycosis in Guatemala City, using the coccidioidin skin test. Doctoral thesis, Facultad de Medicina, Universidad de San Carlos de Guatemala, 1945.Google Scholar
  64. 64.
    Castro A, Trejos A. Confirmation of the first Central American case of coccidioidomycosis. Rev Med Costa Rica. 1951;10:89–90.Google Scholar
  65. 65.
    Perez-Guisasola E, Rosal JE. Human cocciodioidomycosis in Guatemala mycologic, histopatholocic diagnosis and biologic confirmation of the first case. Revista del Colegio Médico de Guatemala. 1960;XI:290–4.Google Scholar
  66. 66.
    Garcia Valdes A, Close de Leon J, Rivera LJ. Coccidioidomycosis communication of the first human case in Guatemala. Revista del Colegio Médico de Guatemala. 1960;XI:284–9.Google Scholar
  67. 67.
    Mayorga RP, Espinoza H. Coccidioidomycosis in Mexico and Central America. Mycopathol Mycol Appl. 1970;41(1):13–23.CrossRefPubMedGoogle Scholar
  68. 68.
    Cordeiro Rde A, et al. Twelve years of coccidioidomycosis in Ceara State, Northeast Brazil: epidemiologic and diagnostic aspects. Diagn Microbiol Infect Dis. 2010;66(1):65–72.CrossRefPubMedGoogle Scholar
  69. 69.
    Giacomazzi J, et al. The burden of serious human fungal infections in Brazil. Mycoses. 2016;59(3):145–50.CrossRefPubMedGoogle Scholar
  70. 70.
    Burwell LA, Park BJ, Wannemuehler KA, Kendig N, Pelton J, Chaput E, et al. Outcomes among inmates treated for coccidioidomycosis at a correctional institution during a community outbreak, Kern County, California, 2004. Clin Infect Dis. 2009;49(11):e113–9.CrossRefPubMedGoogle Scholar
  71. 71.
    Lee LA, Yuan J, Vugia D, Wheeler C, Chapnick R, Mohle-Boetani J. Increased coccidioidomycosis among inmates at a California prison: initial investigation in 2005 to 2006. J Correct Health Care. 2017;23(3):347–52.CrossRefPubMedGoogle Scholar
  72. 72.
    Coccidioidomycosis in California’s adult prisons 2006–2010. California Correctional Health Care Services Public Health Unit and Quality Management; 2012. Google Scholar
  73. 73.
    Laniado-Laborin R. Expanding understanding of epidemiology of coccidioidomycosis in the Western hemisphere. Ann N Y Acad Sci. 2007;1111:19–34.CrossRefPubMedGoogle Scholar
  74. 74.
    Stern NG, Galgiani JN. Coccidioidomycosis among scholarship athletes and other college students, Arizona, USA. Emerg Infect Dis. 2010;16(2):321–3.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Werner SB, Pappagianis D, Heindl I, Mickel A. An epidemic of coccidioidomycosis among archeology students in northern California. N Engl J Med. 1972;286(10):507–12.CrossRefPubMedGoogle Scholar
  76. 76.
    Smith CE, Beard RR, et al. Varieties of coccidioidal infection in relation to the epidemiology and control of the diseases. Am J Public Health Nations Health. 1946;36(12):1394–402.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Diaz JH. Travel-related risk factors for coccidioidomycosis. J Travel Med. 2018;25(1).Google Scholar
  78. 78.
    Panackal AA, Hajjeh RA, Cetron MS, Warnock DW. Fungal infections among returning travelers. Clin Infect Dis. 2002;35(9):1088–95.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Trimble A, Moffat V, Collins AM. Pulmonary infections in the returned traveller. Pneumonia (Nathan). 2017;9(1).Google Scholar
  80. 80.
    Centers for Disease, C. Coccidioidomycosis among persons attending the world championship of model airplane flying—Kern County, California, October 2001. MMWR Morb Mortal Wkly Rep. 2001, 50(49):1106–7.Google Scholar
  81. 81.
    Chaturvedi V, Ramani R, Gromadzki S, Rodeghier B, Chang HG, Morse DL. Coccidioidomycosis in New York State. Emerg Infect Dis. 2000;6(1):25–9.PubMedPubMedCentralGoogle Scholar
  82. 82.
    Desai NR, et al. Coccidioidomycosis in nonendemic area: case series and review of literature. J La State Med Soc. 2010;162(2):97–103.PubMedGoogle Scholar
  83. 83.
    Desai SA, et al. Coccidioidomycosis in non-endemic areas: a case series. Respir Med. 2001;95(4):305–9.CrossRefPubMedGoogle Scholar
  84. 84.
    Brown EM, McTaggart LR, Dunn D, Pszczolko E, Tsui KG, Morris SK, et al. Epidemiology and geographic distribution of blastomycosis, histoplasmosis, and coccidioidomycosis, Ontario, Canada, 1990-2015. Emerg Infect Dis. 2018;24(7):1257–66.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Chandesris MO, et al. Coccidioidomycosis: an imported invasive fungal disease in France. Med Mal Infect. 2008;38(6):336–42.CrossRefPubMedGoogle Scholar
  86. 86.
    Indhirajanti S, et al. Pulmonary coccidioidomycosis: import illness and the importance of travel history. Neth J Med. 2009;67(10):353–5.PubMedGoogle Scholar
  87. 87.
    Pistone T, Lacombe K, Poirot JL, Girard PM, Meynard JL. Imported concomitant coccidioidomycosis and histoplasmosis in an HIV-infected Colombian migrant in France. Trans R Soc Trop Med Hyg. 2005;99(9):712–5.CrossRefPubMedGoogle Scholar
  88. 88.
    Baird RW, Teichtahl H, Ednie HM, Tasiopoulos A, Ryan N, Gee D. A fluffy white traveller: imported Coccidiodes immitis infection in an Australian tourist. Pathology. 1999;31(1):47–50.CrossRefPubMedGoogle Scholar
  89. 89.
    Subedi S, Broom J, Caffery M, Bint M, Sowden D. Coccidioidomycosis in returned Australian travellers. Intern Med J. 2012;42(8):940–3.CrossRefPubMedGoogle Scholar
  90. 90.
    Symmers WS. An Australian case of coccidioidomycosis? Pathology. 1971;3(1):1–8.CrossRefPubMedGoogle Scholar
  91. 91.
    Oberoi JK, Wattal C, Aggarwal PK, Khanna S, Basu AK, Verma K. Pulmonary coccidiomycosis in New Delhi, India. Infection. 2012;40(6):699–702.CrossRefPubMedGoogle Scholar
  92. 92.
    Ogiso A, Ito M, Koyama M, Yamaoka H, Hotchi M, McGinnis MR. Pulmonary coccidioidomycosis in Japan: case report and review. Clin Infect Dis. 1997;25(5):1260–1.CrossRefPubMedGoogle Scholar
  93. 93.
    Verghese S, Arjundas D, Krishnakumar KC, Padmaja P, Elizabeth D, Padhye AA, et al. Coccidioidomycosis in India: report of a second imported case. Med Mycol. 2002;40(3):307–9.CrossRefPubMedGoogle Scholar
  94. 94.
    Jang J, Lee HJ, Lee I, Cho YK, Kim HJ, Sohn KH. The first imported case of pulmonary coccidioidomycosis in Korea. J Korean Med Sci. 1999;14(2):206–9.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Louie L, Ng S, Hajjeh R, Johnson R, Vugia D, Werner SB, et al. Influence of host genetics on the severity of coccidioidomycosis. Emerg Infect Dis. 1999;5(5):672–80.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    McCotter O, Kennedy J, McCollum J, Bartholomew M, Iralu J, Jackson BR, et al. Coccidioidomycosis among American Indians and Alaska Natives, 2001-2014. Open Forum Infect Dis. 2019;6(3):ofz052.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Ampel NM, Dols CL, Galgiani JN. Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. Am J Med. 1993;94(3):235–40.CrossRefPubMedGoogle Scholar
  98. 98.
    Kirkland TN, Fierer J. Coccidioides immitis and posadasii; a review of their biology, genomics, pathogenesis, and host immunity. Virulence. 2018;9(1):1426–35.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Blair JE, Logan JL. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis. 2001;33(9):1536–44.CrossRefGoogle Scholar
  100. 100.
    Masannat FY, Ampel NM. Coccidioidomycosis in patients with HIV-1 infection in the era of potent antiretroviral therapy. Clin Infect Dis. 2010;50(1):1–7.CrossRefPubMedGoogle Scholar
  101. 101.
    Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum. 2004;50(6):1959–66.CrossRefPubMedGoogle Scholar
  102. 102.
    Cole GT, et al. Isolation and morphology of an immunoreactive outer wall fraction produced by spherules of Coccidioides immitis. Infect Immun. 1988;56(10):2686–94.PubMedPubMedCentralGoogle Scholar
  103. 103.
    Cole GT, Kirkland TN, Franco M, Zhu S, Yuan L, Sun SH, et al. Immunoreactivity of a surface wall fraction produced by spherules of Coccidioides immitis. Infect Immun. 1988;56(10):2695–701.PubMedPubMedCentralGoogle Scholar
  104. 104.
    Hung CY, Ampel NM, Christian L, Seshan KR, Cole GT. A major cell surface antigen of Coccidioides immitis which elicits both humoral and cellular immune responses. Infect Immun. 2000;68(2):584–93.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Hung CY, Yu JJ, Seshan KR, Reichard U, Cole GT. A parasitic phase-specific adhesin of Coccidioides immitis contributes to the virulence of this respiratory fungal pathogen. Infect Immun. 2002;70(7):3443–56.CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    • Hung CY, Xue J, Cole GT. Virulence mechanisms of coccidioides. Ann N Y Acad Sci. 2007;1111:225–35 This review discusses some of the key virulence mechanisms for coccidioidal infection that have been discovered such as production of SOWgp and its regulation at certain stages of infection. CrossRefPubMedGoogle Scholar
  107. 107.
    Johannesson H, Townsend JP, Hung CY, Cole GT, Taylor JW. Concerted evolution in the repeats of an immunomodulating cell surface protein, SOWgp, of the human pathogenic fungi Coccidioides immitis and C. posadasii. Genetics. 2005;171(1):109–17.CrossRefPubMedPubMedCentralGoogle Scholar
  108. 108.
    Perfect SE, O'Connell RJ, Green EF, Doering-Saad C, Green JR. Expression cloning of a fungal proline-rich glycoprotein specific to the biotrophic interface formed in the Colletotrichum-bean interaction. Plant J. 1998;15(2):273–9.CrossRefPubMedGoogle Scholar
  109. 109.
    Staab JF, Bradway SD, Fidel PL, Sundstrom P. Adhesive and mammalian transglutaminase substrate properties of Candida albicans Hwp1. Science. 1999;283(5407):1535–8.CrossRefPubMedGoogle Scholar
  110. 110.
    Brady LJ, Cvitkovitch DG, Geric CM, Addison MN, Joyce JC, Crowley PJ, et al. Deletion of the central proline-rich repeat domain results in altered antigenicity and lack of surface expression of the Streptococcus mutans P1 adhesin molecule. Infect Immun. 1998;66(9):4274–82.PubMedPubMedCentralGoogle Scholar
  111. 111.
    Rawlings ND, Tolle DP, Barrett AJ. MEROPS: the peptidase database. Nucleic Acids Res. 2004;32(Database issue):D160–4.CrossRefPubMedPubMedCentralGoogle Scholar
  112. 112.
    Hung CY, Seshan KR, Yu JJ, Schaller R, Xue J, Basrur V, et al. A metalloproteinase of Coccidioides posadasii contributes to evasion of host detection. Infect Immun. 2005;73(10):6689–703.CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Mirbod-Donovan F, Schaller R, Hung CY, Xue J, Reichard U, Cole GT. Urease produced by Coccidioides posadasii contributes to the virulence of this respiratory pathogen. Infect Immun. 2006;74(1):504–15.CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Osterholzer JJ, Surana R, Milam JE, Montano GT, Chen GH, Sonstein J, et al. Cryptococcal urease promotes the accumulation of immature dendritic cells and a non-protective T2 immune response within the lung. Am J Pathol. 2009;174(3):932–43.CrossRefPubMedPubMedCentralGoogle Scholar
  115. 115.
    Mirbod F, Schaller RA, Cole GT. Purification and characterization of urease isolated from the pathogenic fungus Coccidioides immitis. Med Mycol. 2002;40(1):35–44.CrossRefPubMedGoogle Scholar
  116. 116.
    Yu JJ, Smithson SL, Thomas PW, Kirkland TN, Cole GT. Isolation and characterization of the urease gene (URE) from the pathogenic fungus Coccidioides immitis. Gene. 1997;198(1–2):387–91.CrossRefPubMedGoogle Scholar
  117. 117.
    Mobley HL, Island MD, Hausinger RP. Molecular biology of microbial ureases. Microbiol Rev. 1995;59(3):451–80.PubMedPubMedCentralGoogle Scholar
  118. 118.
    Burall LS, Harro JM, Li X, Lockatell CV, Himpsl SD, Hebel JR, et al. Proteus mirabilis genes that contribute to pathogenesis of urinary tract infection: identification of 25 signature-tagged mutants attenuated at least 100-fold. Infect Immun. 2004;72(5):2922–38.CrossRefPubMedPubMedCentralGoogle Scholar
  119. 119.
    Mobley HL. The role of Helicobacter pylori urease in the pathogenesis of gastritis and peptic ulceration. Aliment Pharmacol Ther. 1996;10(Suppl 1):57–64.CrossRefPubMedGoogle Scholar
  120. 120.
    Wise HZ, Hung CY, Whiston E, Taylor JW, Cole GT. Extracellular ammonia at sites of pulmonary infection with Coccidioides posadasii contributes to severity of the respiratory disease. Microb Pathog. 2013;59-60:19–28.CrossRefPubMedGoogle Scholar
  121. 121.
    Nosanchuk JD, Yu JJ, Hung CY, Casadevall A, Cole GT. Coccidioides posadasii produces melanin in vitro and during infection. Fungal Genet Biol. 2007;44(6):517–20.CrossRefPubMedGoogle Scholar
  122. 122.
    Nosanchuk JD, Rosas AL, Lee SC, Casadevall A. Melanisation of Cryptococcus neoformans in human brain tissue. Lancet. 2000;355(9220):2049–50.CrossRefPubMedGoogle Scholar
  123. 123.
    Rosas AL, Nosanchuk JD, Gómez BL, Edens WA, Henson JM, Casadevall A. Isolation and serological analyses of fungal melanins. J Immunol Methods. 2000;244(1–2):69–80.CrossRefPubMedGoogle Scholar
  124. 124.
    Tsai HF, Fujii I, Watanabe A, Wheeler MH, Chang YC, Yasuoka Y, et al. Pentaketide melanin biosynthesis in Aspergillus fumigatus requires chain-length shortening of a heptaketide precursor. J Biol Chem. 2001;276(31):29292–8.CrossRefPubMedGoogle Scholar
  125. 125.
    Schnitzler N, et al. Effect of melanin and carotenoids of Exophiala (Wangiella) dermatitidis on phagocytosis, oxidative burst, and killing by human neutrophils. Infect Immun. 1999;67(1):94–101.PubMedPubMedCentralGoogle Scholar
  126. 126.
    Romero-Martinez R, Wheeler M, Guerrero-Plata A, Rico G, Torres-Guerrero H. Biosynthesis and functions of melanin in Sporothrix schenckii. Infect Immun. 2000;68(6):3696–703.CrossRefPubMedPubMedCentralGoogle Scholar
  127. 127.
    Nosanchuk JD, Casadevall A. The contribution of melanin to microbial pathogenesis. Cell Microbiol. 2003;5(4):203–23.CrossRefPubMedGoogle Scholar
  128. 128.
    Ampel NM, Giblin A, Mourani JP, Galgiani JN. Factors and outcomes associated with the decision to treat primary pulmonary coccidioidomycosis. Clin Infect Dis. 2009;48(2):172–8.CrossRefPubMedGoogle Scholar
  129. 129.
    Blair JE, et al. Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis. Emerg Infect Dis. 2014;20(6):983–90.CrossRefPubMedPubMedCentralGoogle Scholar
  130. 130.
    Hector RF, Laniado-Laborin R. Coccidioidomycosis—a fungal disease of the Americas. PLoS Med. 2005;2(1):e2.CrossRefPubMedPubMedCentralGoogle Scholar
  131. 131.
    Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Geertsma F, Hoover SE, et al. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis. 2016;63(6):e112–46.CrossRefPubMedGoogle Scholar
  132. 132.
    Pilmis B, et al. Antifungal drugs during pregnancy: an updated review. J Antimicrob Chemother. 2015;70(1):14–22.CrossRefPubMedGoogle Scholar
  133. 133.
    Dewsnup DH, Galgiani JN, Graybill JR, Diaz M, Rendon A, Cloud GA, et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med. 1996;124(3):305–10.CrossRefPubMedPubMedCentralGoogle Scholar
  134. 134.
    •• Thompson GR 3rd, et al. Current concepts and future directions in the pharmacology and treatment of coccidioidomycosis. Med Mycol. 2019;57(Supplement_1):S76–84 This paper reviews the management of coccidioidomycosis with triazole and polyene therapy and highlights some potential theurapeutics in the development pipeline. CrossRefPubMedGoogle Scholar
  135. 135.
    Arndt CA, et al. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis. 1988;157(1):178–80.CrossRefPubMedGoogle Scholar
  136. 136.
    Dodds Ashley ES, et al. Pharmacology of systemic antifungal agents. Clin Infect Dis. 2006;43:S28–39.CrossRefGoogle Scholar
  137. 137.
    Thompson GR 3rd, Barker BM, Wiederhold NP. Large-scale evaluation of in vitro amphotericin B, triazole, and echinocandin activity against Coccidioides species from U.S. institutions. Antimicrob Agents Chemother. 2017;61(4).Google Scholar
  138. 138.
    Galgiani, J.N., et al., Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med, 2000. 133(9): p. 676–686.Google Scholar
  139. 139.
    Saravolatz LD, Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36(5):630–7.CrossRefGoogle Scholar
  140. 140.
    Cortez KJ, Walsh TJ, Bennett JE. Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis. 2003;36(12):1619–22.CrossRefPubMedPubMedCentralGoogle Scholar
  141. 141.
    Proia LA, Tenorio AR. Successful use of voriconazole for treatment of Coccidioides meningitis. Antimicrob Agents Chemother. 2004;48(6):2341.CrossRefPubMedPubMedCentralGoogle Scholar
  142. 142.
    Freifeld A, Proia L, Andes D, Baddour LM, Blair J, Spellberg B, et al. Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother. 2009;53(4):1648–51.CrossRefPubMedPubMedCentralGoogle Scholar
  143. 143.
    Kim MM, Vikram HR, Kusne S, Seville MT, Blair JE. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis. 2011;53(11):1060–6.CrossRefPubMedGoogle Scholar
  144. 144.
    Gonzalez GM, Tijerina R, Najvar LK, Bocanegra R, Rinaldi M, Loebenberg D, et al. In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob Agents Chemother. 2002;46(5):1352–6.CrossRefPubMedPubMedCentralGoogle Scholar
  145. 145.
    Lutz JE, Clemons KV, Aristizabal BH, Stevens DA. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob Agents Chemother. 1997;41(7):1558–61.CrossRefPubMedPubMedCentralGoogle Scholar
  146. 146.
    Johnson RH, Einstein HE. Amphotericin B and coccidioidomycosis. Ann N Y Acad Sci. 2007;1111:434–41.CrossRefPubMedGoogle Scholar
  147. 147.
    Seyedmousavi S, et al. Systemic antifungal agents: current status and projected future developments. Methods Mol Biol. 2017;1508:107–39.CrossRefPubMedGoogle Scholar
  148. 148.
    Lindsay J, Sandaradura I, Wong K, Arthur C, Stevenson W, Kerridge I, et al. Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation. J Antimicrob Chemother. 2017;72(12):3414–9.CrossRefPubMedGoogle Scholar
  149. 149.
    Wiederhold NP. Antifungal resistance: current trends and future strategies to combat. Infect Drug Resist. 2017;10:249–59.CrossRefPubMedPubMedCentralGoogle Scholar
  150. 150.
    Kong YC, Levine HB. Experimentally induced immunity in the mycoses. Bacteriol Rev. 1967;31(1):35–53.PubMedPubMedCentralGoogle Scholar
  151. 151.
    Pappagianis D. Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Vaccine Study Group. Am Rev Respir Dis. 1993;148(3):656–60.CrossRefPubMedGoogle Scholar
  152. 152.
    Capilla J, Clemons KV, Liu M, Levine HB, Stevens DA. Saccharomyces cerevisiae as a vaccine against coccidioidomycosis. Vaccine. 2009;27(27):3662–8.CrossRefPubMedGoogle Scholar
  153. 153.
    Zimmermann CR, Johnson SM, Martens GW, White AG, Zimmer BL, Pappagianis D. Protection against lethal murine coccidioidomycosis by a soluble vaccine from spherules. Infect Immun. 1998;66(5):2342–5.PubMedPubMedCentralGoogle Scholar
  154. 154.
    Kirkland TN. The quest for a vaccine against coccidioidomycosis: a neglected disease of the Americas. J Fungi (Basel). 2016;2(4).Google Scholar
  155. 155.
    Xue J, et al. A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis. Infect Immun. 2009;77(8):3196–208.CrossRefPubMedPubMedCentralGoogle Scholar
  156. 156.
    Cole GT, Hung CY, Sanderson SD, Hurtgen BJ, Wüthrich M, Klein BS, et al. Novel strategies to enhance vaccine immunity against coccidioidomycosis. PLoS Pathog. 2013;9(12):e1003768.CrossRefPubMedPubMedCentralGoogle Scholar
  157. 157.
    McCotter OZ, Benedict K, Engelthaler DM, Komatsu K, Lucas KD, Mohle-Boetani JC, et al. Update on the epidemiology of coccidioidomycosis in the United States. Med Mycol. 2019;57(Supplement_1):S30–40.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Hazael Hernandez
    • 1
  • Victor H. Erives
    • 1
  • Luis R. Martinez
    • 1
    Email author
  1. 1.Department of Biological Sciences, The Border Biomedical Research CenterThe University of Texas at El PasoEl PasoUSA

Personalised recommendations